Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €79.97 EUR
Change Today -17.77 / -18.18%
Volume 51.4K
BIO On Other Exchanges
Symbol
Exchange
Xetra
Xetra
OTC US
OTC US
OTC US
As of 3:35 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

biotest ag (BIO) Snapshot

Open
€98.04
Previous Close
€97.75
Day High
€98.41
Day Low
€73.50
52 Week High
03/16/15 - €105.90
52 Week Low
08/12/14 - €68.50
Market Cap
1.1B
Average Volume 10 Days
8.3K
EPS TTM
€1.45
Shares Outstanding
6.6M
EX-Date
05/8/15
P/E TM
55.1x
Dividend
€0.60
Dividend Yield
0.71%
Current Stock Chart for BIOTEST AG (BIO)

Related News

No related news articles were found.

biotest ag (BIO) Related Businessweek News

No Related Businessweek News Found

biotest ag (BIO) Details

Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological medicinal products worldwide. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin for the treatment of haemophilia A acute therapy and prophylaxis; Haemonine for haemophilia B acute therapy and prophylaxis; Bivigam for the treatment of primary immune deficiency; Cytotect for cytomegalovirus (CMV) infections; Fovepta for hepatitis B prophylaxis in newborns; Hepatect CP for the treatment of hepatitis B re-infection prophylaxis; Nabi-HB for post exposure prophylaxis; Intratect for primary immune and secondary antibody deficiency syndromes, as well as for autoimmune diseases; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. The company also provides Albiomin for the treatment of blood volume depletion; Biseko to treat volume and serum protein depletion; Cofact for the treatment of clotting factors deficiency; and Pentaglobin to treat bacterial infections. In addition, its products under development include Indatuximab Ravtansine (BT-062) for multiple myeloma and solid tumors; BT-063 for the treatment of systemic lupus erythematosus; BT-094 (Cytotect 70) to treat CMV infections; Civacir for the treatment of hepatitis C infection; Tregalizumab (BT-061) for rheumatoid arthritis and psoriasis; Fibrinogen to treat fibrinogen deficiency; and IgM concentrate for the treatment of bacterial infections. It has a collaboration agreement with AbbVie for the development of monoclonal antibody BT-061. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany.

2,158 Employees
Last Reported Date: 03/17/15
Founded in 1946

biotest ag (BIO) Top Compensated Officers

Chairman of the Board of Management and Chief...
Total Annual Compensation: €70.0K
Chief Financial Officer, Head of Finances & C...
Total Annual Compensation: €423.0K
Chief Operating Officer and Member of Board o...
Total Annual Compensation: €370.0K
Compensation as of Fiscal Year 2014.

biotest ag (BIO) Key Developments

Biotest AG - Special Call

To discuss topline results from the TREAT 2b study [T cell REgulating Arthritis Trial 2b]

Biotest AG Announces the Results from the TREAT 2b study

Biotest AG announced the results from the TREAT 2b study [T cell REgulating Arthritis Trial 2b], evaluating the efficacy, safety and tolerability of its investigational monoclonal antibody tregalizumab (BT-061) in patients with moderate to severe rheumatoide Arthritis. Initial results indicated that none of the three dosing arms of tregalizumab showed a statistically significant improvement in ACR 20 scores when compared to placebo, the primary efficacy end point of the trial at week 12. The company is in the process of sharing the data with AbbVie, who will decide within 90 days whether to continue the co-development on tregalizumab.

Biotest AG Presents New Clinical and Preclinical Results of Civacir(R) at The 50th International Liver Congress 2015 in Vienna

Biotest announced clinical and preclinical data on Civacir(R), presented at The 50th International Liver Congress 2015 in Vienna, Austria. Currently, there is no approved treatment available to prevent hepatitis C virus recurrence during and after liver transplant surgery. Although direct acting antivirals (DAAs) have the potential to reduce viral load prior to liver transplantation, hepatitis C virus recurrence is frequent. There is still a very high medical need for treatment options preventing reinfection during the critical time during and immediately after transplantation. Data presented at the congress are phase III clinical study data. The study is a randomized, open-label trial conducted in 24 clinical centers in the United States. All patients in the study received antiviral treatment prior to transplantation, mainly new recently approved antivirals. Patients who were treated with the study drug Civacir(R) obtained either 200 mg/kg or 300 mg/kg body weight during and immediately after transplantation. The control group received the standard of care (no antiviral treatment after transplantation). The clinical data shows that 1 out of 21 (5%) reinfection was observed in the high dose group. In contrast 6 out of 20 (30%) and 7 out of 22 (32%) reinfections occurred in the low dose and control group, respectively. Civacir(R) has been well tolerated and no serious adverse events were related to the study drug. More than two-thirds of the planned patients have been enrolled in the ongoing clinical trial. The preclinical study presented demonstrates activity of Civacir(R) against different hepatitis C virus escape variants. The data shows that Civacir(R) may potently and dose-dependently neutralize all virus variants tested including variants resistant to neutralizing host antibodies.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIO:GR €79.97 EUR -17.77

BIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BIO.
View Industry Companies
 

Industry Analysis

BIO

Industry Average

Valuation BIO Industry Range
Price/Earnings 48.9x
Price/Sales 1.6x
Price/Book 2.0x
Price/Cash Flow 24.5x
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOTEST AG, please visit www.biotest.de. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.